AI-Powered

AI-Powered

AI-Powered

Cognitive Care fora Better Tomorrow

Cognitive Care fora Better Tomorrow

Cognitive Care fora Better Tomorrow

Revolutionizing dementia assessment and therapy with Generative AI. Personalized, engaging, and effective solutions for cognitive health.

20%

Reduction in agitation and depressive symptoms

Reduction in agitation and depressive symptoms

30%

Increase in patient participation and engagement

Increase in patient participation and engagement

83%

Reduction in caregiver labor costs

Reduction in caregiver labor costs

90%

Reduction in treatment
expenses

Reduction in treatment
expenses

70%+

Correlation with MMSE cognitive scores

Correlation with MMSE cognitive scores

Clinical Results That Matter

MindVoyage delivers measurable impact on cognitive and emotional health while reducing the burden of care.

Clinical Research

The effectiveness of MindVoyage digital cognitive therapy was demonstrated through a randomized controlled trial.

We have completed the clinical trial of MindVoyage digital cognitive therapy. The study used a randomized assignment design, with the treatment group undergoing an 8-week digital therapy intervention, 2-3 times per week.

Trial Design

After the principal investigator evaluates the matters related to the outpatient trial and explains them to the subjects to obtain consent, clinical trial personnel will arrange to conduct multiple assessments of cognitive function and executive function impairment. The researchers will guide the subjects in using MindVoyage.

Test Duration

20

weeks

Assessment and Tracking

week 0

week 8

week 16

Baseline Assessment

Post-Test Assessment

Follow-Up Assessment

All participants will undergo cognitive therapy assessments at Week 0 (Baseline), Week 8 (Post-Test), and Week 16 (Follow-Up).

Intervention group

Intervention group

MindVoyage

MindVoyage

Digital Therapy

Digital Therapy

8 weeks, 2–3 sessions per week

8 weeks, 2–3 sessions per week

Exercise

Exercise

Dietary Education

Dietary Education

control group

control group

Exercise

Exercise

Dietary Education

Dietary Education

Participants were randomly assigned into two groups.
The intervention group received exercise and nutrition education at Week 0, followed by an 8-week digital therapy intervention (2–3 sessions per week).
The control group received only exercise and nutrition education at Week 0.

Cognitive Function Assessment – MMSE
V1V2252321191715

2.17

pt

average improvement in cognitive function

Intervention

control

Delirium Assessment – FAM-CAM
V1V232.521.5

21.4

%

reduction in agitation behaviors

Intervention

control

Depression Scale – GDS
V1V25.54.53.52.51.5

23.1

%

average improvement in cognitive function

Intervention

control

Cognitive Function Assessment – MMSE
V1V2252321191715

2.17

pt

average improvement in cognitive function

Intervention

control

Delirium Assessment – FAM-CAM
V1V232.521.5

21.4

%

reduction in agitation behaviors

Intervention

control

Depression Scale – GDS
V1V25.54.53.52.51.5

23.1

%

average improvement in cognitive function

Intervention

control

Cognitive Function Assessment – MMSE
V1V2252321191715

2.17

pt

average improvement in cognitive function

Intervention

control

Delirium Assessment – FAM-CAM
V1V232.521.5

21.4

%

reduction in agitation behaviors

Intervention

control

Depression Scale – GDS
V1V25.54.53.52.51.5

23.1

%

average improvement in cognitive function

Intervention

control

Research results

After 24 sessions (approximately eight weeks) of using MindVoyage, clinical evaluations showed:

Validation of Assessment Tool

The built-in Brainmate Score shows a high positive correlation with the clinically common MMSE dementia assessment scale (r = 0.70), indicating that MindVoyage's digital cognitive assessment results are highly correlated with traditional clinical assessment scales. This suggests it can serve as an effective auxiliary tool for clinical diagnosis.
Regression Line (r=0.7014934)

Brainmate Score vs MMSE

67.57072.57577.580.082.5252321191715

Correlation between Brainmate Score and MMSE Dementia Assessment Scale

International Patents & Academic Publications

Economic Benefits

save

93

%

compared to traditional dementia medications

MindVoyage

NT$

51,000

/ year

Dementia Medications

NT$

800,000

/ year

MindVoyage

NT$

51,000

/ year

Dementia Medications

NT$

800,000

/ year

save

98

%

compared to dementia village care

MindVoyage

NT$

51,000

/ year

Dementia Medications

NT$

800,000

/ year

MindVoyage

NT$

51,000

/ year

Dementia Medications

NT$

800,000

/ year

Service Benefits

83

%

Reduction in labor costs

Originally, cognitive therapy and assessment were conducted in a one-on-one format.

 With MindVoyage, it can be transformed into a one-to-many model, allowing multiple users to interact simultaneously.

 Labor cost per participant is reduced by approximately 83%, effectively improving service capacity.

30

%

Increase in patient engagement and participation

MindVoyage also significantly boosts patient engagement.

 Overall participation increased by approximately 30%,

 which helps promote long-term and consistent care.

Cost-effectiveness and Care Impact

Brainmate’s cognitive system is protected by patents across multiple countries and has been published in peer-reviewed international journals — demonstrating both its technological innovation and clinical value.
Key Journal Publications

2022

Domain-Specific Cognitive Prosthesis for Face Memory and Recognition

Diagnostics (Basel),

12(9):2242

2025

Biodesign in the generative AI era: enhancing innovation and equity with NLP and LLM tools

BMJ Health & Care Informatics,

32(1):e101409

Digital Cognitive Care, Warm Companionship

Brainmate aims to bridge the gap between AI and human-centered care, ensuring that every patient receives personalized, effective, and compassionate cognitive support.

Brainmate aims to bridge the gap between AI and human-centered care, ensuring that every patient receives personalized, effective, and compassionate cognitive support.

Executive Function Task UI
Executive Function Task UI
Executive Function Task UI
The patient follows the prompts from Brainmate's MindVoyage to grasp and move the props for cognitive therapy.
The patient follows the prompts from Brainmate's MindVoyage to grasp and move the props for cognitive therapy.
The patient follows the prompts from Brainmate's MindVoyage to grasp and move the props for cognitive therapy.

Our Mission

Our Mission

At Brainmate, we are dedicated to transforming dementia care through AI-driven cognitive assessment and therapy.

At Brainmate, we are dedicated to transforming dementia care through AI-driven cognitive assessment and therapy.

By leveraging Generative AI, we create engaging, interactive experiences that help individuals preserve cognitive function, improve emotional well-being, and enhance their quality of life.

By leveraging Generative AI, we create engaging, interactive experiences that help individuals preserve cognitive function, improve emotional well-being, and enhance their quality of life.

See MindVoyage
in Action

Experience how AI can support therapy and bring peace of mind